VRTXVertex Pharmaceuticals
What is the market doing?
No clear lean: rangebound and lightly shorted.
Choppy, but holding above its 200-day average. Price is +8% vs its 200-day average.
Lightly shorted, settled Sep 15, 2026, about a week of normal trading to cover. Up 1.2% since the previous count, unchanged over three months.
Against the whole market›
Percentile against every name Ryufin tracks. Higher is better; the tick marks the middle of the market. Context, not one of the checks above.
Where this answer is blind. Insider selling is often routine (taxes, diversification); only cluster buying is a strong tell.
How VRTX is trading
Vertex Pharmaceuticals is +32% over the past year while the S&P 500 is +18%: 14 points ahead of the market.
1-year return · S&P 500 +18%
- vs 200-day average
- +8.2%
vs 200-day average · close to trend
- RSI (14)
- 50
RSI (14) · neutral
- Below its 52-week high
- 8.6%
Below its 52-week high
Details›
- Last close2026-10-09
- $510.18
- 1 monthS&P 500 +2.7%
- −0.89%
- 1 yearS&P 500 +18%
- +32%
- 5 yearsS&P 500 +88%
- +168%
- vs 50-day average$519.38
- −1.8%
- 52-week high
- $558.12
- 52-week low
- $376.62
- Annualised volatility
- 32%
| Year | Return |
|---|---|
| 2026 (year to date) | +13% |
| 2025 | +13% |
| 2024 | −1.0% |
| 2023 | +41% |
| 2022 | +32% |
| 2021 | −7.1% |
| 2020 | +7.9% |
| 2019 | +32% |
| 2018 | +11% |
| 2017 | +103% |
| Month | Years | Positive | Average |
|---|---|---|---|
| Jan | 10 | 9 of 10 | +9.1% |
| Feb | 10 | 3 of 10 | −1.3% |
| Mar | 10 | 6 of 10 | +3.6% |
| Apr | 10 | 6 of 10 | +0.87% |
| May | 10 | 5 of 10 | +1.4% |
| Jun | 10 | 9 of 10 | +4.6% |
| Jul | 11 | 7 of 11 | +2.7% |
| Aug | 11 | 7 of 11 | +1.3% |
| Sep | 11 | 3 of 11 | −3.1% |
| Oct | 11 | 6 of 11 | −1.3% |
| Nov | 10 | 7 of 10 | +3.6% |
| Dec | 10 | 5 of 10 | +0.23% |
End-of-day closes from IEX; the S&P 500 comparison uses SPY over the same window. Prices are a reference point, not a basis for trading decisions.
Biotechnology
The closest names by size in the same industry